Skip to Content

Join the 'Eylea' group to help and get support from people like you.

Eylea News

Study Compares Drugs for Common Diabetic Eye Disease

Posted 29 Feb 2016 by Drugs.com

MONDAY, Feb. 29, 2016 – People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease – Avastin, Eylea and Lucentis – vary widely in price, but new research suggests all work equally well for patients with mild vision loss. However, when diabetic macular edema leads to more severe vision loss, researchers found Eylea to be the better choice. The study, funded by the U.S. National Eye Institute (NEI), "will help doctors and their patients with diabetic macular edema choose the most appropriate therapy," study lead author Dr. John Wells said in an institute news release. "The study suggests there is little advantage of choosing Eylea or Lucentis over [much cheaper] Avastin when a patient's loss of visual acuity from macular edema is mild, meaning a visual acuity of 20/40 or better," Wells explained. ... Read more

Related support groups: Eye Conditions, Macular Degeneration, Avastin, Diabetes Mellitus, Lucentis, Macular Edema, Eylea, Abnormal Glucose Tolerance, Bevacizumab, Visual Defect/Disturbance, Diabetic Macular Edema, Ranibizumab, Aflibercept

FDA OKs New Drug for Diabetes-Linked Eye Condition

Posted 26 Mar 2015 by Drugs.com

WEDNESDAY, March 25, 2015 – The U.S. Food and Drug Administration on Wednesday approved the use of Eylea, an injected drug, to treat diabetic retinopathy in patients with diabetic macular edema. According to the U.S. Centers for Disease Control and Prevention, diabetic retinopathy is a leading cause of blindness in American adults. A third of those over 40 with diabetes have some form of the eye condition, according to 2008 data, the CDC said. Overall, more than 29 million people in the United States have type 1 or type 2 diabetes, and diabetes remains the leading cause of new blindness among people aged 20 to 74, the CDC noted. In some people who have diabetic retinopathy with macular edema, abnormal new blood vessels grow on the surface of the retina. If those new blood vessels break, severe vision loss or blindness can occur. "The major cause of vision loss occurs when abnormal ... Read more

Related support groups: Eylea, Diabetic Retinopathy

Eylea Approval Expanded to Include Diabetic Retinopathy

Posted 26 Mar 2015 by Drugs.com

WEDNESDAY, March 25, 2015 – U.S. Food and Drug Administration approval of Eylea (aflibercept) has been expanded to treat diabetic retinopathy among people with diabetic macular edema, the agency said Wednesday in a news release. Affecting more than 29 million people in the U.S., diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness, the FDA said. Among some people who have vision-impairing diabetic macular edema, diabetic retinopathy can spur the growth of abnormal blood vessels on the eye's retina. If these vessels burst, it can lead to severe vision loss or blindness. The injected drug Eylea is intended to be used in tandem with appropriate therapies to control blood sugar, blood pressure and cholesterol, the FDA said. The drug's safety and effectiveness were evaluated in clinical studies involving nearly 680 people. The most common side ... Read more

Related support groups: Eylea, Diabetic Retinopathy, Aflibercept

FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema

Posted 25 Mar 2015 by Drugs.com

March 25, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema. Diabetic retinopathy (DR) is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and Prevention, diabetes (type 1 and type 2) affects more than 29 million people in the United States and is the leading cause of new blindness among people ages 20 to 74 years. In 2008, 33 percent of adults with diabetes aged 40 years or older had some form of DR. In some cases of DR with diabetic macular edema (DME), abnormal new blood vessels grow on the surface of the retina. Severe vision loss or blindness can occur if the new blood vessels break. “Diabetes is a serious public health crisis, affecting more patients ... Read more

Related support groups: Eylea, Diabetic Retinopathy, Diabetic Macular Edema, Aflibercept

Study Compares Drugs for Diabetes-Linked Eye Disease

Posted 18 Feb 2015 by Drugs.com

WEDNESDAY, Feb. 18, 2015 – A vision-robbing condition called diabetic macular edema can strike people with diabetes. Now, a new study compared three leading drugs for the condition – Avastin, Eylea and Lucentis – and found that Eylea came out on top, at least for patients with "moderate" vision loss. The study, funded by the U.S. National Eye Institute (NEI), "will have a dramatic impact on patient care," said Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City. He was not involved in the new research. According to the NEI, about 750,000 Americans suffer from diabetic macular edema. The condition occurs in people with a type of diabetes-related eye disease called diabetic retinopathy. "Diabetic macular edema is the most common reason for visual loss in the 7.7 million Americans with diabetic retinopathy," Fromer noted. "Macular edema occurs when abnormal blood ... Read more

Related support groups: Lucentis, Eylea, Diabetic Retinopathy, Diabetic Macular Edema, Retinopathy Prophylaxis

Eylea (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema

Posted 31 Jul 2014 by Drugs.com

TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of Eylea in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although Eylea may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when Eylea was dosed every 4 weeks compared to every 8 weeks. "Diabetic macular edema is a leading cause of vision loss among working-age adults in the U.S., and we are pleased to be able to offer a new treatment option to these patients," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "Our clinical studies have demonstrated ... Read more

Related support groups: Eylea, Diabetic Macular Edema, Aflibercept

Ask a Question

Further Information

Related Condition Support Groups

Macular Degeneration, Diabetic Macular Edema, Macular Edema, Diabetic Retinopathy

Eylea Patient Information at Drugs.com